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Abstract
An appellate court in the United States affirmed the Patent Office’s finding that the Broad Institute’s patents cov-
ering eukaryotic applications of CRISPR-Cas9 was separately patentable over the University of California’s (UC)
earlier patent application. This does not bode well for future negotiations between UC and the Broad Institute,
even as nuclease technology continues to eclipse the original dispute. This perspective explores the appellate
decision, where UC goes from here, and what this all means for scientists in the future.
Introduction
On September 10, 2018, the U.S. Court of Appeals for
the Federal Circuit announced its decision in the ea-
gerly awaited CRISPR*-Cas9 patent appeal.1 The court
affirmed the U.S. Patent Trial and Appeal Board’s
(PTAB) decision that there was ‘‘no interference-in-
fact’’ between the University of California’s (UC) now
famous patent application and a dozen of the Broad Insti-
tute’s patents for eukaryotic applications of the technolo-
gy.{ In sum, the court concluded that using CRISPR-Cas9
in eukaryotic cells—at least, when the Broad Institute’s
patent application was filed in late 2012—was patent-
ability distinct from UC’s earlier disclosures of the tech-
nology in vitro.
There has been a considerable amount of ink spilled—
some of it mine—on the merits of the decision itself.2,3
But it bears repeating that the decision, while likely legally
correct, does not altogether mesh with the way research
science is actually practiced. It is one of an increasing
number of instances where science and patent law seem
misaligned.
There are now perhaps four things to think about fol-
lowing the decision: (1) where UC goes from here; (2)
what this means for UC’s currently pending patent appli-
cation; (3) what this means for future negotiations be-
tween UC and the Broad Institute; and (4) what this all
means for scientists and commercial developers using
CRISPR technology.
1. Where Does UC Go from Here?
The Federal Circuit’s affirmance of the U.S. PTAB deci-
sion stands as a ‘‘loss’’ in the UC’s win–loss column. UC
wanted the interference—it petitioned for it—so the
PTAB’s ‘‘no interference in fact’’ decision at least cut
against UC’s professed desire. The Federal Circuit’s af-
firmance was in favor of the Broad, which argued from
the beginning that it was engaged in different work. To
that end, UC could ask for two forms of appeal: either a
rehearing from the Federal Circuit but with a full panel
of 12 judges, not simply the original three who decided
the immediate case (a rehearing en banc in legal parlance),
or a petition to the Supreme Court of the United States to
hear the case.
Either form of appeal is unlikely to proceed. For a re-
hearing en banc, the Federal Circuit, writ large, agrees to
hear such cases either where the original panel got its
facts wrong or where the larger issue is of such impor-
tance to an understanding of patent law doctrine that a
hearing from the entire court is needed. This simply
isn’t likely here. As noted in Judge Moore’s Federal Cir-
cuit decision, this case was simply a straightforward
application of deferring to the PTAB’s findings.1 The
PTAB, in other words, may have gotten things wrong,
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but its factual conclusions deserve deference. That’s en-
tirely a correct reading of the law. The Federal Circuit
does not retry cases; it only looks for legal errors. This
is an important but perhaps subtly missed point by most
scientists. Just as in criminal prosecutions, it is exceed-
ingly rare to get two jury trials.
UC could also appeal to the Supreme Court in a ‘‘peti-
tion for certiorari.’’ There too the possibility of the Supreme
Court hearing the case is unlikely. ‘‘Cert petitions’’ are typ-
ically granted where there is a novel legal issue in dispute
or widespread disagreement among courts as to the inter-
pretation of a particular law. In other cases, the Supreme
Court hears cases because the effect of the Court’s deci-
sion is likely to alter millions of lives. There are, to put it
bluntly, not any of these cases. There are no novel legal
issues in dispute; there is no contest as to how to interpret
‘‘no interference in fact’’ decisions from the PTAB; and
the case, despite its technical importance, is unlikely to
change millions of lives.
2. What Is the Status of UC’s Patent Application?
The Federal Circuit’s decision now means UC must go
back to the Patent Office to salvage from it what it can.
This is important: the Patent Office’s decision on UC’s
patent application is unlikely to be the rubber stamp
that some commentators have made it out to be.4 Using
the analogy forwarded by the UC during the pendency
of the interference, simply because the PTAB decided
there wasn’t an interference, does not mean UC will get
a patent covering ‘‘all tennis balls,’’ while the Broad Insti-
tute’s eukaryotic patents will cover only green ones. Patent
examiners can, and in some cases must, ‘‘reopen prosecu-
tion’’ of patent applications following a no interference-in-
fact decision.5 And in high-profile cases such as this, with
an expansive PTAB decision that goes well beyond the
merits of simply whether an interference occurred, it
would be surprising if the examiner did otherwise.
This is significant because of two documents that
issued from the Patent Office during UC’s case. The
first is the PTAB’s own no interference-in-fact decision
that said in no uncertain terms that UC did not sufficiently
describe or enable eukaryotic work in its patent applica-
tion. Again, there are many reasons to doubt this from a
scientific perspective, as I wrote earlier,6 but it is likely
true as a matter of patent law. The second document is
Virginijus Šikšnys’s patent, disclosing ribonucleic CRISPR-
Cas9 gene-editing complexes that also issued during that
time (see Table 1).7 Šikšnys’s patent was filed 6 weeks
before UC’s, and while patent applications are secret
for the first 18 months after they are filed, if they are
issued, they can be used against future patent applications
according to the date they were filed not merely pub-
lished. Though this may seem like a rare circumstance,
there is a provision of the patent statute that deals specif-
ically with this exact situation, x102(e).
Given that, what path forward is there for UC’s patent
application? The PTAB’s decision and Šikšnys’s patent
sit as the Scylla and Charybdis for UC’s continued pros-
ecution of its application. The navigable routes are likely
claims covering gene editing using CRISPR-Cas9 but
only through endogenous expression of Cas9 in prokary-
otic cells. That of course is incredible narrow—it ex-
cludes RNP-mediated editing (as in Šikšnys) and all
eukaryotic applications. But the method is still important
for some applications, such as agriculture, which use
expressed CRISPR-Cas9 to transform bacteria. Important
single-guide, expressed CRISPR-Cas9 work is being con-
ducted in Agrobacterium tumefaciens, for example.8
3. Is There Anything for UC
and the Broad to Negotiate?
If those do end up as UC’s claims, is there anything for
the two sides to negotiate? Does UC have any leverage
whatsoever? UC does have some; there is still some un-
certainty regarding the dispute—what lawyers refer to
as a ‘‘nuisance cost’’—that is worth the parties at least
sitting down to try to hammer things out. And beyond
that, both sides likely want to save face from what has
by and large been a source of embarrassment for two oth-
erwise upstanding institutions. Such a settlement could be
a cross-royalty agreement, where both sides receive roy-
alties from licensing each other’s patents (although the
Broad would presumably take the lion’s share). The par-
ties could also pool their patents, with royalties flowing to
a new institution that would fund research efforts be-
tween UC and the Broad.9 But these are hypotheticals;
how the two sides will resolve their differences remains
unclear, especially given the geographic differences in
how the dispute continues to unfold. It is fair to say the
Broad has ‘‘won’’ the CRISPR-Cas9 dispute here in the
United States. However, the Broad has lost the majority
of its patents on the same technology in Europe—a
Table 1. Important Dates in the CRISPR-Cas9 Interference
Šikšnys files patent March 20, 2012
UC files patent application May 25, 2012
Broad files first patent December 12, 2012
UC requests PTO declare an interference April 13, 2015
PTO declares an interference January 11, 2016
Interference oral argument December 6, 2016
PTAB interference decision February 15, 2017
Interference appeal April 12, 2017
Appeal oral argument April 30, 2018
Appeal decision September 10, 2018
UC, University of California; PTO, Patent and Trademark Office; PTAB,




























































dispute that is still ongoing and unlikely to be resolved
any time soon. It is not as if UC has no leverage to ne-
gotiate; it’s simply that its leverage is weak.
4. What Does this Mean for Scientists
and Commercial Developers?
Academic scientists need not worry about the Federal
Circuit’s decision. CRISPR research should proceed as
usual. Many CRISPR researchers’ institutions already
have licenses from both institutions, typically through
constructs deposited with Addgene, a nonprofit reposi-
tory of CRISPR plasmids.10 Beyond that, it is wholly un-
likely that either institution—UC or the Broad—would
sue other institutions for patent infringement, even if
those institutions’ researchers practiced the patented
technology without a license. While there is no U.S. ‘‘re-
search exemption’’ from patent infringement, the vast
majority of CRISPR research seems covered by licenses,
materials transfer agreements, or beneficence.
For for-profit companies, however, the decision is a
bigger deal. Using CRISPR-Cas9 technology for thera-
peutic applications without a license from the Broad
would be seriously problematic. This includes CRISPR
Therapeutics and Intellia, who have stood shoulder-to-
shoulder with UC during the dispute’s trying times.11
Those companies, if they continue to use Cas9, are ulti-
mately going to need to visit the Broad, hat in hand, and
somehow bargain for a license. And after the heat of the
patent dispute between UC and the Broad, the Broad may
well be obdurate. To some degree, you can’t blame them.
The UC’s supposed refusal to negotiate and petition for
an interference imposed tens of millions of dollars’ worth
of attorneys costs on the Broad and Editas.12 Any license
from the Broad to CRISPR Therapeutics or Intellia may
seek to recoup those costs or at least some fraction of
them. It’s wholly unclear whether the companies would
be willing to do so.
Conclusion
All of this—the patents, the dispute, the angst, and the
bad blood—may be obviated by the rapid development
of CRISPR technology. It is worth underscoring that
the dispute only covers CRISPR Type II systems using
Cas9. However, there is now a menagerie of enzymes—
some natural, others recombinant—that work as well, or
better, or in other contexts.13 This development of the
CRISPR technology—new enzymes, new systems, new
applications, and new researchers—is what The CRISPR
Journal is all about. New enzymes may very well make
the patent dispute between UC and the Broad rather
quaint. The dispute, and the Federal Circuit’s decision,
may have been important in their time, but like science
generally, CRISPR too marches on.
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